Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Commercial Eyes Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Australian Parliament, aims to regulate therapeutic goods, including medicines, medical devices, and blood products, to ensure their safety, quality, and efficacy. This legislation establishes a framework for the approval, manufacturing, and distribution of therapeutic goods, ensuring that they meet established standards before they are made available to the public. One of the Act's primary objectives is to address gaps in the regulation of therapeutic goods, ensuring that the public is protected from potentially harmful products. The Therapeutic Goods Administration (TGA), a department within the Australian Government's Department of Health, is responsible for administering the Act and ensuring compliance with its provisions. The policy objective of the Act is to safeguard public health by maintaining high standards for therapeutic goods, thereby preventing harm to consumers and promoting access to safe and effective products.

Scope and Application

The Therapeutic Goods Act 1989 applies to various persons, entities, and industries involved in the importation, supply, and advertisement of therapeutic goods within Australia. This includes pharmaceutical products, medical devices, and other goods that are regulated for safety and efficacy. The Act has a national reach, governing therapeutic goods across the Commonwealth, states, and territories of Australia. The Act can extend or restrict its application through subordinate instruments, such as regulations and orders, which provide further detail on specific aspects of therapeutic goods regulation. In this instance, the Act applies to the importation and supply of Aripiprazole (Abilify) tablets by Commercial Eyes Pty Ltd, with certain conditions attached to the consent granted by the delegate of the Secretary of the Department of Health. The consent provided under sections 14 and 14A of the Act allows for the importation and supply of Aripiprazole tablets that do not conform to certain labelling requirements, subject to specific conditions designed to ensure the safety and efficacy of the therapeutic goods.

Key Provisions

The main operative sections of this legislation, specifically subsections 14 and 14A of the Therapeutic Goods Act 1989, pertain to the granting of consent for the importation and supply of therapeutic goods that do not fully conform to certain regulatory requirements. In this instance, the consent was given for Aripiprazole (Abilify) tablets in various strengths, provided by Commercial Eyes Pty Ltd, to be imported and supplied without the labels bearing the name and address of the current sponsor, as stipulated in paragraph 3(2)(l) of the Therapeutic Goods Order No. 69 (subsection 14(1)). The consent was granted from 26 June 2015 until 30 June 2016 (subsection 14A(1)). The Act also requires that the labels used are those previously approved for the former sponsor, Bristol-Myers Squibb Australia Pty Ltd, and that there are arrangements in place with the former sponsor for the prompt referral of any queries or complaints to the current sponsor, Otsuka Australia Pharmaceutical Pty Ltd (subsection 15(1)). The obligations imposed on the parties under this Act include adherence to the conditions stipulated in the consent. Commercial Eyes Pty Ltd must ensure that the labels used are those previously approved by the Therapeutic Goods Administration and are not updated to reflect the current sponsor's details. Moreover, they must maintain a communication channel with the former sponsor, Bristol-Myers Squibb Australia Pty Ltd, to facilitate the prompt referral of any consumer queries or complaints to the current sponsor, Otsuka Australia Pharmaceutical Pty Ltd. This ensures that any consumer issues are appropriately addressed by the responsible party. The Therapeutic Goods Act 1989 does not explicitly state specific offences, penalties, or consequences for breach in this context. However, any failure to comply with the conditions of the consent or the broader requirements of the Act could potentially result in enforcement actions by the Therapeutic Goods Administration. These actions might include product recalls, fines, or legal proceedings under the broader regulatory framework of the Act. The specific penalties for non-compliance would be determined based on the nature and severity of the breach, in accordance with the Act's provisions on penalties and enforcement.